No increase in fractures after stopping hormone therapy: Results from the women's health initiative

Journal of Clinical Endocrinology and Metabolism

Volumn 102, Issue 1, 2017, Pages 302-308

  Watts, Nelson B ^a   Cauley, Jane A ^b   Jackson, Rebecca D ^c   LaCroix, Andrea Z ^d   Lewis, Cora E ^e   Manson, Jo Ann E ^f   Neuner, Joan M ^g   Phillips, Lawrence S ^h,i   Stefanick, Marcia L ^j   Wactawski Wende, Jean ^k   Crandall, Carolyn ^l  

^a Mercy Health Osteoporosis and Bone Health Services   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e University of Alabama at Birmingham   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h ATLANTA VA MEDICAL CENTER   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY AT BUFFALO   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE; PLACEBO; VITAMIN D;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CALCIUM INTAKE; CONTROLLED STUDY; ETHNICITY; FALLING; FEMALE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; MENOPAUSE; OSTEOPOROSIS; PHYSICAL ACTIVITY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT DURATION; TREATMENT WITHDRAWAL; VITAMIN INTAKE; ADVERSE EFFECTS; COMPARATIVE STUDY; FOLLOW UP; HIP FRACTURES; HORMONE SUBSTITUTION; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PROGNOSIS; WOMEN'S HEALTH;

FEMALE; FOLLOW-UP STUDIES; HIP FRACTURES; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PROGNOSIS; WITHHOLDING TREATMENT; WOMEN'S HEALTH;

EID: 85010611255     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-3270     Document Type: Article

References (17)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, StefanickML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative randomized controlled trial. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized trial. JAMA. 2002; 288(3):321-333.
2. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB; Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA. 2003; 290(13):1729-1738.
3. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, StefanickML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA. 2004; 291(14):1701-1712.
4. Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SA, Ko MG, Naughton MJ, Satterfield S, Bassford T; Women's Health Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res. 2006; 21(6):817-828.
5. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004; 291(1):47-53.
6. Yates J, Barrett-Connor E, Barlas S, Chen Y-T, Miller PD, Siris ES. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol. 2004; 103(3):440-446.
7. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SAA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008; 299(9):1036-1045.
8. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA. 2011; 305(13):1305-1314.
9. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310(13):1353-1368.
10. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998; 19(1):61-109.
11. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA,Mulloy AL, Heyden N,WuM, Kaur A, Lombardi A. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002; 137(11):875-883.
12. Wasnich RD, Bagger YZ, Hosking DJ,McClung MR,WuM,Mantz AM, Yates JJ, Ross PD, Alexandersen P, Ravn P, Christiansen C, Santora AC II; Early Postmenopausal Intervention Cohort Study Group. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause. 2004; 11(6):622-630.
13. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J; Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-termcontinued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone. 2008; 43(2):222-229.
14. Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN,Compston J, Reid IR, Vanderschueren D, Cosman F. Postmenopausal osteoporosis treatment with antiresorptives: effect of discontinuation or long-term continuation on bone turnover and fracture risk-A perspective. J Bone Miner Res. 2012; 27 (5):2414-2415.
15. Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int. 2016; 27(5):1917-1921.
16. Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int. 2016; 27(5):1923-1925.
17. Anastasilakis AD, Makras P. Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int. 2016; 27(5):1929-1930.